Figure 1 Mechanisms of kidney injury in the setting of obesity

Slides:

Advertisements

Similar presentations

Efferent arteriole Afferent arteriole.

Advertisements

Figure 1 Schematic representation of idiopathic nephrotic syndrome,

Figure 1 Disruption of phosphate homeostasis in chronic kidney disease (CKD) Figure 1 | Disruption of phosphate homeostasis in chronic kidney disease (CKD).

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Proinflammatory mechanisms in CKD

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 The fat–intestine–kidney axis

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Pathologic features of obesity-related glomerulopathy (ORG)

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Podocyte dysfunction is a common feature of renal injury

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic.

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Figure 2 Prevention of antigen–antibody

filtration rate (GFR), and sodium (Na+) excretion

Figure 4 Effects of glucagon-like peptide 1 (GLP-1) and

Figure 2 Roles of mTOR complexes in the kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

cardiovascular and renal systems

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Loss of the glycocalyx leads to podocyte and kidney injury

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Nephrol. doi: /nrneph

Kidney Disease and the Westernization and Industrialization of Food

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Hypothetical effect of starting therapy for autosomal

Figure 4 Podocyte–endothelial cross talk and activation of heparanase

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Pathophysiological events and preventive

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Patient, facility, health-care system and industry factors

Figure 3 Preventive strategies for CSA-AKI

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Figure 2 Haemodynamic alterations in obesity

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Presentation transcript:

Figure 1 Mechanisms of kidney injury in the setting of obesity Figure 1 | Mechanisms of kidney injury in the setting of obesity. Obesity, especially morbid obesity, can induce afferent vasodilation in order to augment glomerular filtration rate. Glomerular autoregulation might be impaired and elevated systemic blood pressures could then be transmitted to the glomerular capillaries leading to barotrauma. Glomerular capillary dilation might heighten susceptibility to barotrauma, and the need for podocytes to cover a larger surface area could lead to proteinuria. Câmara, N. O. S. et al. (2017) Kidney disease and obesity: epidemiology, mechanisms and treatment Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.191